Loading...
BE PHARMACEUTICALS INC — Enoxaparin Import Profile: Suppliers, Formulations & Sources
Loading...
Pharmaceutical Importer · #3 buyer for Enoxaparin · $6.8M import value · 144 shipments · UNITED STATES · DGFT Verified
BE PHARMACEUTICALS INC is the #3 importer of Enoxaparin from India with $6.8M in import value and 144 verified shipments. BE PHARMACEUTICALS INC holds a 4.4% market share in Enoxaparin imports based in UNITED STATES. The company sources from 2 verified suppliers across 43 formulations shipped to 1 country.
Verified from 144 customs shipment records
| Supplier | Value | Shipments | % Share |
|---|---|---|---|
| BIOLOGICAL E. LIMITED | $5.9M | 125 | 86.1% |
| BIOLOGICAL E LIMITED | $946.8K | 19 | 13.9% |
BE PHARMACEUTICALS INC sources Enoxaparin from 2 verified Indian suppliers based on 144 customs records. The primary supplier is BIOLOGICAL E. LIMITED accounting for 86.1% of imports.
Buyers ranked immediately above and below #3 by import value
| # | Buyer | Country | Import Value | Shipments | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | FRESENIUS KABI USA, LLC | UNITED STATES | $20.6M | 412 | $50.0K |
| 2 | BOSTON ONCOLOGY ARABIA | SAUDI ARABIA | $12.8M | 255 | $50.0K |
| 3 | BE PHARMACEUTICALS INC ★ | UNITED STATES | $6.9M | 138 | $50.0K |
| 8 | FRESENIUS KABI CANADA LTD | CANADA | $4.3M | 87 | $50.0K |
| 4 | FRESENIUS KABI USA LLC |
BE PHARMACEUTICALS INC ranks #3 among 505 Enoxaparin importers from India. Average shipment value of $50.0K compared to the market average of $116.5K. The closest competitors by value are FRESENIUS KABI USA, LLC and BOSTON ONCOLOGY ARABIA.
Destination countries from 144 verified shipments
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $6.8M | 144 | 100.0% |
BE PHARMACEUTICALS INC imports Enoxaparin to 1 country. The primary destination is UNITED STATES receiving 100.0% of shipments worth $6.8M.
| Formulation | Value | Shipments |
|---|---|---|
| ENOXAPARIN SODIUM INJECTION USP 40MG/0.4ML | $1.8M | 36 |
| ENOXAPARIN SODIUM INJECTION USP 40MG/0.4MLNOS | $459.5K | 11 |
| ENOXAPARIN SODIUM INJECTION USP 30MG/0.3ML | $412.2K | 9 |
| ENOXAPARIN SODIUM INJECTION USP 60MG/0.6ML | $348.1K | 8 |
| ENOXAPARIN SODIUM INJECTION USP 80MG/0.8ML | $300.0K | 6 |
| ENOXAPARIN SODIUM INJECTION USP 100MG/1ML | $290.9K | 6 |
| ENOXAPARIN SODIUM INJECTION USP 40MG/0.4 | $200.0K | 4 |
| ENOXAPARIN SODIUM INJECTION USP 80MG/0.8 | $200.0K | 4 |
| ENOXAPARIN SODIUM INJECTION USP 40MG/04ML |
What BE PHARMACEUTICALS INC and other importers must comply with to import Enoxaparin from India
U.S. Food and Drug Administration (FDA)
Abbreviated New Drug Application (ANDA) for generic drugs, requiring bioequivalence studies and compliance with 21 CFR. Indian manufacturing sites must pass FDA pre-approval inspection.
Typical timeline: 10–18 months for ANDA approval
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA prior to approval
India exported $58.9M worth of Enoxaparin through 3,309 shipments from 223 suppliers to 118 countries, serving 505 buyers globally. BE PHARMACEUTICALS INC imports $6.8M of this total, accounting for 4.4% of India's Enoxaparin exports with 144 shipments from UNITED STATES. This is verified from 144 customs shipment records covering 43 distinct formulations.
BE PHARMACEUTICALS INC's average Enoxaparin order value is $47.3K per consignment, based on 144 shipments totaling $6.8M. BE PHARMACEUTICALS INC is based in UNITED STATES and ranks #3 among all Enoxaparin importers from India by value. The company sources from 2 verified suppliers in India.
BE PHARMACEUTICALS INC sources Enoxaparin from 2 verified Indian suppliers: BIOLOGICAL E. LIMITED ($5.9M, 86.1%), BIOLOGICAL E LIMITED ($946.8K, 13.9%). This is based on 144 customs records.
BE PHARMACEUTICALS INC ranks #3 among 505 Enoxaparin importers from India with a 4.4% market share. The top 3 importers are FRESENIUS KABI USA, LLC ($20.6M), BOSTON ONCOLOGY ARABIA ($12.8M), BE PHARMACEUTICALS INC ($6.9M). BE PHARMACEUTICALS INC processed 144 shipments from UNITED STATES.
Latest developments and market context
Detailed market intelligence for Enoxaparin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify import regulations and drug registration requirements with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access order-level details, pricing data, supplier connections, and competitive analysis for BE PHARMACEUTICALS INC's Enoxaparin imports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
BE PHARMACEUTICALS INC
Company Profile
Multiple products · $0 total trade · Multiple categories
| UNITED STATES |
| $3.5M |
| 70 |
| $50.0K |
| $187.8K |
| 4 |
| ENOXAPARIN SODIUMINJECTION USP 100MG/1ML | $150.0K | 3 |
BE PHARMACEUTICALS INC imports 43 distinct Enoxaparin formulations from India. The top formulation is ENOXAPARIN SODIUM INJECTION USP 40MG/0.4ML with 36 shipments worth $1.8M.
Drug Listing with FDA; Import Alert screening; Customs entry via FDA PREDICT system
US-specific labeling per 21 CFR 201 including NDC number, lot, expiry, dosage in English
Note: Subject to FDA Import Alerts and Automatic Detention if facility has open Form 483 observations.
Regulatory information is provided for general reference based on publicly available FDA guidelines for pharmaceutical imports. Requirements may vary by specific drug formulation, dosage form, and therapeutic classification. Importers should consult directly with FDA or qualified regulatory affairs professionals for case-specific guidance.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 118+ countries, 505+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Verified from customs records
Access shipment-level records, supplier contacts, and formulation details for BE PHARMACEUTICALS INC.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Enoxaparin. For current order-level data, contact TransData Nexus.